FOLH1 and posterior cortical atrophy: Additionally, the small-molecule ligand radionuclide-coupled diagnostic agent 68Ga-PSMA-11 was approved in 2020 by the U.S. Food and Drug Administration (FDA) for the clinical diagnosis of PCa [15].